Mocaciclib (Q901)
Phase 2A selective CDK7 inhibitor that finished Phase 1 dose escalation in January 2026 and started dosing in a Phase 2 combination trial with fulvestrant in HR+/HER2- breast cancer.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has completed Phase 1 of its CDK7 inhibitor and moved into a Phase 2 breast cancer combination trial.
Roles often seen at this stageClinical & PV · Research & development · BD & licensing
A drug developer working on cancer candidates such as the CDK7 inhibitor mocaciclib and on telacebec for tuberculosis and Buruli ulcer.
A selective CDK7 inhibitor that finished Phase 1 dose escalation in January 2026 and started dosing in a Phase 2 combination trial with fulvestrant in HR+/HER2- breast cancer.
A candidate for tuberculosis, Buruli ulcer and leprosy; the TREAT-BU trial supports an approval filing in Buruli ulcer.
A preclinical HER2-targeted dual-payload ADC candidate.
A candidate prioritized for chronic graft-versus-host disease, acute myeloid leukemia and histiocytosis.
Finished Phase 1 dose escalation of mocaciclib and set the recommended Phase 2 dose.
Started dosing in a Phase 2 trial of mocaciclib with fulvestrant in HR+/HER2- breast cancer.
Presented mocaciclib Phase 1 results at ESMO 2026.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.